| UniProt ID | ENAH_HUMAN | |
|---|---|---|
| UniProt AC | Q8N8S7 | |
| Protein Name | Protein enabled homolog | |
| Gene Name | ENAH | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 591 | |
| Subcellular Localization | Cytoplasm. Cytoplasm, cytoskeleton. Cell projection, lamellipodium. Cell projection, filopodium. Cell junction, synapse. Cell junction, focal adhesion. Targeted to the leading edge of lamellipodia and filopodia by MRL family members. Colocalizes at f | |
| Protein Description | Ena/VASP proteins are actin-associated proteins involved in a range of processes dependent on cytoskeleton remodeling and cell polarity such as axon guidance and lamellipodial and filopodial dynamics in migrating cells. ENAH induces the formation of F-actin rich outgrowths in fibroblasts. Acts synergistically with BAIAP2-alpha and downstream of NTN1 to promote filipodia formation (By similarity).. | |
| Protein Sequence | MSEQSICQARAAVMVYDDANKKWVPAGGSTGFSRVHIYHHTGNNTFRVVGRKIQDHQVVINCAIPKGLKYNQATQTFHQWRDARQVYGLNFGSKEDANVFASAMMHALEVLNSQETGPTLPRQNSQLPAQVQNGPSQEELEIQRRQLQEQQRQKELERERLERERMERERLERERLERERLERERLEQEQLERERQERERQERLERQERLERQERLERQERLDRERQERQERERLERLERERQERERQEQLEREQLEWERERRISSAAAPASVETPLNSVLGDSSASEPGLQAASQPAETPSQQGIVLGPLAPPPPPPLPPGPAQASVALPPPPGPPPPPPLPSTGPPPPPPPPPLPNQVPPPPPPPPAPPLPASGFFLASMSEDNRPLTGLAAAIAGAKLRKVSRMEDTSFPSGGNAIGVNSASSKTDTGRGNGPLPLGGSGLMEEMSALLARRRRIAEKGSTIETEQKEDKGEDSEPVTSKASSTSTPEPTRKPWERTNTMNGSKSPVISRRDSPRKNQIVFDNRSYDSLHRPKSTPLSQPSANGVQTEGLDYDRLKQDILDEMRKELTKLKEELIDAIRQELSKSNTA | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 2 | Phosphorylation | ------MSEQSICQA ------CCHHHHHHH | 44.32 | 24043423 | |
| 2 | Acetylation | ------MSEQSICQA ------CCHHHHHHH | 44.32 | 19413330 | |
| 5 | Phosphorylation | ---MSEQSICQARAA ---CCHHHHHHHHEE | 22.68 | 24043423 | |
| 14 | Sulfoxidation | CQARAAVMVYDDANK HHHHEEEEEEECCCC | 1.66 | 30846556 | |
| 16 | Phosphorylation | ARAAVMVYDDANKKW HHEEEEEEECCCCCE | 7.04 | - | |
| 21 | Acetylation | MVYDDANKKWVPAGG EEEECCCCCEEECCC | 50.13 | 26051181 | |
| 66 | Acetylation | VINCAIPKGLKYNQA EEEEECCCCCCCCCC | 71.42 | 26051181 | |
| 69 | Ubiquitination | CAIPKGLKYNQATQT EECCCCCCCCCCCCC | 51.31 | 21890473 | |
| 69 | Acetylation | CAIPKGLKYNQATQT EECCCCCCCCCCCCC | 51.31 | 26051181 | |
| 69 | Ubiquitination | CAIPKGLKYNQATQT EECCCCCCCCCCCCC | 51.31 | 21890473 | |
| 69 (in isoform 1) | Ubiquitination | - | 51.31 | 21890473 | |
| 69 | Malonylation | CAIPKGLKYNQATQT EECCCCCCCCCCCCC | 51.31 | 26320211 | |
| 69 (in isoform 2) | Ubiquitination | - | 51.31 | 21890473 | |
| 116 | Phosphorylation | EVLNSQETGPTLPRQ HHHHCCCCCCCCCCC | 40.60 | - | |
| 119 | Phosphorylation | NSQETGPTLPRQNSQ HCCCCCCCCCCCCCC | 51.22 | - | |
| 125 (in isoform 2) | Phosphorylation | - | 25.42 | 18669648 | |
| 125 | Phosphorylation | PTLPRQNSQLPAQVQ CCCCCCCCCCCCHHC | 25.42 | 25159151 | |
| 136 | Phosphorylation | AQVQNGPSQEELEIQ CHHCCCCCHHHHHHH | 52.18 | 23403867 | |
| 265 | Phosphorylation | WERERRISSAAAPAS HHHHHHHCCCCCCCC | 16.47 | 20736484 | |
| 266 | Phosphorylation | ERERRISSAAAPASV HHHHHHCCCCCCCCC | 21.40 | 20736484 | |
| 284 | Phosphorylation | LNSVLGDSSASEPGL HHHHHCCCCCCCCCC | 26.46 | 20736484 | |
| 405 | Phosphorylation | GAKLRKVSRMEDTSF HHHHHHHHCCCCCCC | 29.01 | 23927012 | |
| 410 | Phosphorylation | KVSRMEDTSFPSGGN HHHCCCCCCCCCCCC | 20.97 | 23927012 | |
| 411 | Phosphorylation | VSRMEDTSFPSGGNA HHCCCCCCCCCCCCC | 47.70 | 23927012 | |
| 414 | Phosphorylation | MEDTSFPSGGNAIGV CCCCCCCCCCCCEEC | 58.27 | 30576142 | |
| 423 | Phosphorylation | GNAIGVNSASSKTDT CCCEECCCCCCCCCC | 27.41 | 21406692 | |
| 425 | Phosphorylation | AIGVNSASSKTDTGR CEECCCCCCCCCCCC | 31.99 | 21406692 | |
| 426 | Phosphorylation | IGVNSASSKTDTGRG EECCCCCCCCCCCCC | 39.01 | 21406692 | |
| 428 | Phosphorylation | VNSASSKTDTGRGNG CCCCCCCCCCCCCCC | 40.52 | 28111955 | |
| 430 | Phosphorylation | SASSKTDTGRGNGPL CCCCCCCCCCCCCCC | 33.73 | 28111955 | |
| 442 | Phosphorylation | GPLPLGGSGLMEEMS CCCCCCCCHHHHHHH | 27.27 | 27251275 | |
| 449 | Phosphorylation | SGLMEEMSALLARRR CHHHHHHHHHHHHHH | 21.03 | 28111955 | |
| 461 | Acetylation | RRRRIAEKGSTIETE HHHHHHHHCCCCCHH | 49.49 | 23954790 | |
| 461 | Ubiquitination | RRRRIAEKGSTIETE HHHHHHHHCCCCCHH | 49.49 | - | |
| 463 (in isoform 3) | Phosphorylation | - | 36.96 | 28450419 | |
| 463 | O-linked_Glycosylation | RRIAEKGSTIETEQK HHHHHHCCCCCHHCC | 36.96 | 30059200 | |
| 463 | Phosphorylation | RRIAEKGSTIETEQK HHHHHHCCCCCHHCC | 36.96 | 22617229 | |
| 464 | Phosphorylation | RIAEKGSTIETEQKE HHHHHCCCCCHHCCC | 31.34 | 23911959 | |
| 464 | O-linked_Glycosylation | RIAEKGSTIETEQKE HHHHHCCCCCHHCCC | 31.34 | 30059200 | |
| 465 (in isoform 3) | Phosphorylation | - | 7.07 | 23927012 | |
| 467 | Phosphorylation | EKGSTIETEQKEDKG HHCCCCCHHCCCCCC | 39.61 | 23403867 | |
| 467 | O-linked_Glycosylation | EKGSTIETEQKEDKG HHCCCCCHHCCCCCC | 39.61 | 30059200 | |
| 469 (in isoform 3) | Phosphorylation | - | 62.95 | 25159151 | |
| 470 | Acetylation | STIETEQKEDKGEDS CCCCHHCCCCCCCCC | 62.74 | 26051181 | |
| 471 (in isoform 3) | Phosphorylation | - | 65.73 | 28731282 | |
| 473 | Acetylation | ETEQKEDKGEDSEPV CHHCCCCCCCCCCCC | 66.35 | 26051181 | |
| 475 (in isoform 3) | Phosphorylation | - | 65.19 | 23927012 | |
| 477 | O-linked_Glycosylation | KEDKGEDSEPVTSKA CCCCCCCCCCCCCCC | 39.23 | 30059200 | |
| 477 | Phosphorylation | KEDKGEDSEPVTSKA CCCCCCCCCCCCCCC | 39.23 | 25159151 | |
| 479 (in isoform 3) | Phosphorylation | - | 38.34 | 22496350 | |
| 480 (in isoform 3) | Phosphorylation | - | 9.18 | 18669648 | |
| 481 | Phosphorylation | GEDSEPVTSKASSTS CCCCCCCCCCCCCCC | 34.91 | 23403867 | |
| 481 | O-linked_Glycosylation | GEDSEPVTSKASSTS CCCCCCCCCCCCCCC | 34.91 | 30059200 | |
| 482 | Phosphorylation | EDSEPVTSKASSTST CCCCCCCCCCCCCCC | 26.85 | 23403867 | |
| 482 | O-linked_Glycosylation | EDSEPVTSKASSTST CCCCCCCCCCCCCCC | 26.85 | 30059200 | |
| 483 | Ubiquitination | DSEPVTSKASSTSTP CCCCCCCCCCCCCCC | 42.81 | - | |
| 485 | Phosphorylation | EPVTSKASSTSTPEP CCCCCCCCCCCCCCC | 37.57 | 23927012 | |
| 486 | Phosphorylation | PVTSKASSTSTPEPT CCCCCCCCCCCCCCC | 31.10 | 30266825 | |
| 487 | Phosphorylation | VTSKASSTSTPEPTR CCCCCCCCCCCCCCC | 33.84 | 30266825 | |
| 488 | Phosphorylation | TSKASSTSTPEPTRK CCCCCCCCCCCCCCC | 43.86 | 30266825 | |
| 489 | Phosphorylation | SKASSTSTPEPTRKP CCCCCCCCCCCCCCC | 31.59 | 29255136 | |
| 493 | Phosphorylation | STSTPEPTRKPWERT CCCCCCCCCCCCCCC | 50.06 | 23927012 | |
| 500 | Phosphorylation | TRKPWERTNTMNGSK CCCCCCCCCCCCCCC | 24.43 | 23927012 | |
| 500 (in isoform 2) | Phosphorylation | - | 24.43 | 28450419 | |
| 502 | Phosphorylation | KPWERTNTMNGSKSP CCCCCCCCCCCCCCC | 16.05 | 23927012 | |
| 502 (in isoform 2) | Phosphorylation | - | 16.05 | 23927012 | |
| 506 (in isoform 2) | Phosphorylation | - | 25.59 | 25159151 | |
| 506 | Phosphorylation | RTNTMNGSKSPVISR CCCCCCCCCCCCCCC | 25.59 | 30278072 | |
| 508 (in isoform 2) | Phosphorylation | - | 26.54 | 28731282 | |
| 508 | Phosphorylation | NTMNGSKSPVISRRD CCCCCCCCCCCCCCC | 26.54 | 30278072 | |
| 512 (in isoform 2) | Phosphorylation | - | 22.84 | 23927012 | |
| 512 | Phosphorylation | GSKSPVISRRDSPRK CCCCCCCCCCCCCCC | 22.84 | 23927012 | |
| 516 | Phosphorylation | PVISRRDSPRKNQIV CCCCCCCCCCCCEEE | 25.45 | 24732914 | |
| 516 (in isoform 2) | Phosphorylation | - | 25.45 | 22496350 | |
| 517 (in isoform 2) | Phosphorylation | - | 56.40 | 18669648 | |
| 527 | Methylation | NQIVFDNRSYDSLHR CEEEECCCCCCCCCC | 38.14 | 115483147 | |
| 528 | Phosphorylation | QIVFDNRSYDSLHRP EEEECCCCCCCCCCC | 39.28 | 23312004 | |
| 529 | Phosphorylation | IVFDNRSYDSLHRPK EEECCCCCCCCCCCC | 13.30 | 30183078 | |
| 531 | Phosphorylation | FDNRSYDSLHRPKST ECCCCCCCCCCCCCC | 20.17 | 25159151 | |
| 536 | Ubiquitination | YDSLHRPKSTPLSQP CCCCCCCCCCCCCCC | 67.90 | - | |
| 537 | Phosphorylation | DSLHRPKSTPLSQPS CCCCCCCCCCCCCCC | 37.63 | 30266825 | |
| 538 | Phosphorylation | SLHRPKSTPLSQPSA CCCCCCCCCCCCCCC | 34.08 | 30266825 | |
| 541 | Phosphorylation | RPKSTPLSQPSANGV CCCCCCCCCCCCCCC | 41.05 | 30278072 | |
| 544 | Phosphorylation | STPLSQPSANGVQTE CCCCCCCCCCCCCCC | 27.08 | 26657352 | |
| 550 | Phosphorylation | PSANGVQTEGLDYDR CCCCCCCCCCCCHHH | 29.61 | 23403867 | |
| 553 (in isoform 2) | Ubiquitination | - | 4.48 | 21890473 | |
| 559 | Ubiquitination | GLDYDRLKQDILDEM CCCHHHHHHHHHHHH | 46.98 | - | |
| 559 | 2-Hydroxyisobutyrylation | GLDYDRLKQDILDEM CCCHHHHHHHHHHHH | 46.98 | - | |
| 574 (in isoform 1) | Ubiquitination | - | 51.18 | 21890473 | |
| 574 | Ubiquitination | RKELTKLKEELIDAI HHHHHHHHHHHHHHH | 51.18 | 21890473 | |
| 574 | Acetylation | RKELTKLKEELIDAI HHHHHHHHHHHHHHH | 51.18 | 26051181 | |
| 574 | 2-Hydroxyisobutyrylation | RKELTKLKEELIDAI HHHHHHHHHHHHHHH | 51.18 | - | |
| 574 | Ubiquitination | RKELTKLKEELIDAI HHHHHHHHHHHHHHH | 51.18 | 21890473 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
| 265 | S | Phosphorylation | Kinase | PKA | - | Uniprot |
| Modified Location | Modified Residue | Modification | Function | Reference |
|---|---|---|---|---|
| 265 | S | Phosphorylation |
| - |
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of ENAH_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| ABI1_HUMAN | ABI1 | physical | 12672821 | |
| ZYX_HUMAN | ZYX | physical | 12672821 | |
| ZYX_HUMAN | ZYX | physical | 10801818 | |
| MK01_HUMAN | MAPK1 | physical | 21988832 | |
| SEPT7_HUMAN | SEPT7 | physical | 22863883 | |
| CSN4_HUMAN | COPS4 | physical | 22863883 | |
| EVL_HUMAN | EVL | physical | 26344197 | |
| RAC1_HUMAN | RAC1 | physical | 19277120 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-125; SER-506 ANDSER-508, AND MASS SPECTROMETRY. | |
| "ATM and ATR substrate analysis reveals extensive protein networksresponsive to DNA damage."; Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.; Science 316:1160-1166(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-125, AND MASSSPECTROMETRY. | |
| "Global proteomic profiling of phosphopeptides using electron transferdissociation tandem mass spectrometry."; Molina H., Horn D.M., Tang N., Mathivanan S., Pandey A.; Proc. Natl. Acad. Sci. U.S.A. 104:2199-2204(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-125; SER-405; THR-410;THR-502 AND SER-508, AND MASS SPECTROMETRY. | |
| "Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-508, AND MASSSPECTROMETRY. | |
| "A probability-based approach for high-throughput proteinphosphorylation analysis and site localization."; Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; Nat. Biotechnol. 24:1285-1292(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-489, AND MASSSPECTROMETRY. | |